[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479078":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":47,"collaborators":50,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All",null,"Blood sampling and an MRI will be conducted alongside standard stroke cognitive tests upon enrollment. A follow-up three-month visit will check for adverse events and a follow-up cognitive stroke test. At 12 months, an MRI will be conducted alongside a cognitive test.",[13],"Diagnostic Test: Medical Imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Medical Imaging","magnetic resonance imaging",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"David Liebeskind, MD","CONTACT","‭(310) 963-5539‬","dliebeskind@mednet.ucla.edu",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Ronald Reagan UCLA Medical Center","RECRUITING","Los Angeles","California","90095","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-118.24368,34.05223,{"lat":39,"lon":38},[42,45],{"name":43,"role":23,"phone":10,"phoneExt":10,"email":44},"Ryan Apfel","rapfel@mednet.ucla.edu",{"name":22,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"David Liebeskind","Neurology Professor",[51,53,55,57,59,61],{"name":52,"class":6},"University of Pittsburgh Medical Center",{"name":54,"class":6},"University of Chicago",{"name":56,"class":6},"Bay State Clinical Trials, Inc.",{"name":58,"class":6},"Yale University",{"name":60,"class":6},"University of Vermont",{"name":62,"class":6},"University of Southern California","100479078","platelet-expression-of-fcriia-and-arterial-hemodynamics-to-predict-recurrent-stroke-in-intracranial-atherosclerosis-100479078",false,"NCT05518305","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis","Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosi","FCG","Inclusion Criteria:\n\n* Stroke is defined as symptoms lasting \\>24 hours and associated with imaging evidence of acute ischemia in the distribution of the stenotic vessel on head CT or brain MRI. Minor stroke is defined as NIHSS\\\u003C6, as used in prior studies.\n* Eligible TIA, defined as transient neurological symptoms lasting \\\u003C24 hours, need to be: a) accompanied by DWI abnormalities in the distribution of the stenotic artery; or b) multiple (\\>1), stereotyped events associated with unequivocal ischemic symptoms (i.e. weakness, aphasia, diplopia), and attributed to the symptomatic artery. The intent of these restrictive inclusion criteria for TIA is to exclude potential stroke mimics.\n* ICAD should involve the intracranial carotid, middle cerebral, intracranial vertebral or basilar arteries. Isolated anterior and posterior cerebral artery stenosis is not included as it is uncommon in these locations and non-invasive criteria for high-grade ICAD are not well established for these vessels.\n* Stenosis 50-99% will be quantified by CTA. The criteria for 50-99% are: measured stenosis by WASID criteria (percent stenosis = (1-\\[diameter stenosis\u002Fdiameter normal\\]) x 100%.\n* Age ³30; those 30-49 years of age must also have the presence of established atherosclerotic disease in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years). The rationale for this criterion is to exclude non-atherosclerotic vasculopathies.\n* Provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Other determined etiology or established cause of the acute stroke or TIA: atrial fibrillation, mitral stenosis, mechanical valve, intracardiac thrombus or vegetation, dilated cardiomyopathy or ejection fraction \\\u003C30%, proximal extracranial carotid or vertebral stenosis \\>50%.\n* Contraindications to MRI, including MR-incompatible metallic implants (i.e. certain artificial cardiac valves, penile implants, other prosthesis), implanted electronic devices (i.e. pacemaker\u002Fdefibrillator, neurostimulators, cochlear implants), other potentially mobile ferromagnetic material (i.e. shrapnel, magnetic aneurysm clips), pregnancy (women in fertile age should have a negative pregnancy test), lactation, morbid obesity, and severe claustrophobia.",true,"ALL","30 Years",{"count":75,"type":76},250,"ESTIMATED","OBSERVATIONAL","An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.",[80,81,82,83],"Stroke","TIA","Ischemic Stroke","Ischemic",[80],"2026-06-09",{"date":87,"type":88},"2026-06-11","ACTUAL",{"date":90,"type":88},"2022-09-30",{"date":92,"type":76},"2027-09-30",{"name":5,"class":6},1]